OrthoPediatrics (KIDS) Expected to Release Earnings on Tuesday

OrthoPediatrics (NASDAQ:KIDS) is projected to post its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to post earnings of ($0.2250) per share and revenue of $68.50 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 4:30 PM ET.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. The business had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. On average, analysts expect OrthoPediatrics to post ($1.14) EPS for the current fiscal year and ($0.83) EPS for the next fiscal year.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS opened at $24.50 on Monday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The stock has a fifty day moving average price of $23.01 and a 200 day moving average price of $20.23. OrthoPediatrics has a 1-year low of $14.42 and a 1-year high of $26.74. The company has a market cap of $639.70 million, a PE ratio of -14.58 and a beta of 0.99.

Analysts Set New Price Targets

KIDS has been the topic of several recent research reports. BTIG Research reissued a “buy” rating and issued a $29.00 price objective on shares of OrthoPediatrics in a research note on Monday, September 14th. Truist Financial upgraded shares of OrthoPediatrics to a “hold” rating in a research note on Thursday, October 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Finally, Needham & Company LLC increased their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, OrthoPediatrics has a consensus rating of “Moderate Buy” and an average target price of $26.50.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, Director David R. Pelizzon sold 302,369 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the transaction, the director directly owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This represents a 4.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Squadron Capital Llc sold 302,369 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the transaction, the insider directly owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,100,000 shares of company stock worth $46,747,931 over the last 90 days. Company insiders own 32.50% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.